12 Sep 2024 by admin in UncategorizedComments Zenas BioPharma Announces Pricing of Upsized Initial Public Offering
03 Sep 2024 by admin in UncategorizedComments Avenzo Therapeutics Announces Clinical Study Collaboration with Gilead Sciences to Evaluate AVZO-021 and Trodelvy® in HR+/HER2- Metastatic Breast Cancer
20 Aug 2024 by admin in UncategorizedComments Renowned Myeloma Experts Dr. Kenneth C. Anderson and Dr. Shaji Kumar join Scientific Advisory Board of Oricell Therapeutics
19 Aug 2024 by admin in UncategorizedComments Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors
08 Aug 2024 by admin in UncategorizedComments Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
15 Jul 2024 by admin in UncategorizedComments Oricell Therapeutics’ GPRC5D-Targeted CAR-T Therapy, OriCAR-017, Receives FDA Fast Track Designation for Relapsed/Refractory Multiple Myeloma
15 Jul 2024 by admin in UncategorizedComments Eluminex Biosciences Announces First Patient Dosed in the Phase 1b LOTUS Trial of the Novel Trispecific Fusion Antibody EB-105 in Diabetic Macular Edema (DME)
09 Jul 2024 by admin in UncategorizedComments nterius BioTherapeutics Receives HREC Approval and CTN Clearance from the TGA to Commence a Phase 1 Clinical Trial for Its First-in-Class In Vivo CAR Therapeutic for B Cell Malignancies
01 Jul 2024 by admin in UncategorizedComments Zenas BioPharma Appoints Orlando Oliveira as Chief Commercial Officer July 1, 2024
25 Jun 2024 by admin in UncategorizedComments Alebund’s Innovative Investigational Drug AP306 Receives NMPA’s Breakthrough Therapy Designation (BTD) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease (CKD)
15 May 2024 by admin in UncategorizedComments Sail Biomedicines Appoints Clinical and Scientific Leader Dr. Wendy Chung to Its Board
15 May 2024 by admin in UncategorizedComments Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
13 May 2024 by admin in UncategorizedComments RareStone Group Announces Appointment of Andy Zhang and Hardy Huan as Co-CEOs
07 May 2024 by admin in UncategorizedComments Zenas BioPharma Announces Upsized $200 Million Series C Financing to Advance Mid- and Late-Stage Immunology-Focused Clinical Development Programs
06 May 2024 by admin in UncategorizedComments Adcentrx Therapeutics Announces China NMPA Grants IND Clearance for ADRX-0706, a Novel Nectin-4 ADC for the Treatment of Advanced Solid Tumors
30 Apr 2024 by admin in UncategorizedComments Eluminex Biosciences Announces FDA Acceptance of Investigational New Drug (IND) Application for EB-105 – A Novel Trispecific Fusion Antibody for Diabetic Macular Edema (DME) – and Upcoming Scientific Presentations
26 Apr 2024 by admin in UncategorizedComments Crescendo Biologics announces that Zai Lab has initiated a global Phase 2 clinical trial evaluating ZL-1102 (Humabody®, CB001) as a topical treatment for psoriasis
08 Apr 2024 by admin in UncategorizedComments Adcentrx Therapeutics Appoints Meng Jiang as Chief Financial Officer
29 Mar 2024 by admin in UncategorizedComments Alebund’s Innovative Investigational Drug AP303 Receives FDA Orphan Drug Designation (ODD) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
26 Mar 2024 by admin in UncategorizedComments Avenzo Therapeutics Announces $150 Million Oversubscribed Financing To Advance Emerging Oncology Pipeline
06 Mar 2024 by admin in UncategorizedComments Zenas BioPharma Appoints Patricia Allen to its Board of Directors
07 Feb 2024 by admin in UncategorizedComments Sail Biomedicines Appoints Kerry Benenato, Ph.D., as Chief Platform Officer
29 Jan 2024 by admin in UncategorizedComments Oricell Announces FDA Clearance of IND Application for OriCAR- 017, a novel GPRC5D Targeted CAR-T Cell Therapy Utilizing the Company’s Proprietary Platform, for the Treatment of Relapsed/Refractory Multiple Myeloma
25 Jan 2024 by admin in UncategorizedComments Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
18 Jan 2024 by admin in UncategorizedComments NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders
15 Jan 2024 by admin in UncategorizedComments Sail Biomedicines Provides Update on Research with Cystic Fibrosis Foundation and Pioneering Medicines
04 Jan 2024 by admin in UncategorizedComments Sail Biomedicines Appoints Tech and Pharma Industry Veteran Frank D’Amelio to Its Board
03 Jan 2024 by admin in UncategorizedComments Sail Biomedicines Receives Grants to Fight Malaria by Developing a New Class of RNA Medicines
19 Dec 2023 by admin in UncategorizedComments Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants
13 Dec 2023 by admin in UncategorizedComments Alebund Reports Update for AP306 (EOS789), a First-in-Class Pan- inhibitor of Sodium-dependent Phosphate Transporters, from a Completed Phase II Clinical Trial in Patients with Hyperphosphatemia on Hemodialysis
06 Dec 2023 by admin in UncategorizedComments Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine
06 Dec 2023 by admin in UncategorizedComments Crescendo Biologics announces first U.S. patients dosed in expanded Phase 1b clinical trial of CB307 for patients with mCRPC
05 Dec 2023 by admin in UncategorizedComments Adcentrx Announces Extension of Series A+ Financing to $51 Million
05 Dec 2023 by admin in UncategorizedComments Zenas BioPharma Strengthens Executive Leadership with Appointment of Jennifer Fox as Chief Business Officer and Chief Financial Officer and Tanya Fischer, M.D., PhD. as Head of R&D and Chief Medical Officer
04 Dec 2023 by admin in UncategorizedComments Zenas BioPharma Strengthens Executive Leadership with Appointment of Jennifer Fox as Chief Business Officer and Chief Financial Officer and Tanya Fischer, M.D., PhD. as Head of R&D and Chief Medical Officer
15 Nov 2023 by admin in UncategorizedComments ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP
19 Oct 2023 by admin in UncategorizedComments Flagship Pioneering Announces the Merger of Two Leading Programmable Medicine Platforms to form Sail
